Pharmacists gain expanded prescribing powers

Summary#

AB 35, “Revises provisions governing pharmacists,” would amend Nevada laws on pharmacy, drugs, laboratories and health coverage, and add a new section to pharmacy law. Its stated goal is to let pharmacists provide a wider range of care; that goal is not a guaranteed result. The bill is prefiled and is not law.

  • Pharmacists could prescribe and dispense FDA-approved drugs and devices for previously diagnosed or self-limiting conditions, and for acute conditions diagnosed after a federally classified “waived” test (a test considered low risk). They could also provide a one-time refill without another practitioner’s approval when, in the pharmacist’s professional judgment, losing access would harm the patient.
  • Pharmacists could order certain laboratory tests, perform waived tests, and collect specimens using methods beyond fingersticks and oral or nasal swabs. The bill would also require regulations allowing pharmacists to direct certain exempt laboratories, even without a collaborative practice agreement.
  • The bill would authorize pharmacists to administer drugs and possess and administer controlled substances and dangerous drugs, subject to applicable rules and limits.
  • The new prescribing and refill authority would not cover non-FDA-approved drugs or devices. It would restrict controlled drugs, with exceptions for some non-opioid controlled drugs in specified care settings. The bill’s text bars opioids under this new authority.
  • The State Board of Pharmacy could set the scope, standard of care and liability-insurance requirements for the new prescribing and refill authority. It could suspend or revoke a pharmacist’s registration for failing to comply with the law or regulations.

What it means for you#

  • Patients: A pharmacist could provide some treatment or a one-time refill without approval from another kind of practitioner. The bill does not require pharmacists to offer these services, and it does not set out an application, review or appeal process.
  • Pharmacists: The bill would expand their authority to prescribe, dispense, test, collect specimens and administer drugs. Some activities would be limited by the conditions in the bill and by any rules the Board adopts.
  • Laboratories: Regulations would have to allow a pharmacist to serve as director of an exempt laboratory. The bill defines this as a licensed lab that performs only specified low-risk tests and/or provider-performed microscopy, and does not perform only HIV testing.
  • Insured people and health plans: The bill says its changes do not alter existing coverage requirements for certain HIV-prevention services. It does not clearly require coverage for all newly authorized pharmacist services.
  • General public: The bill would not require anyone to use a pharmacist for these services or require pharmacists to provide them.

Money#

The fiscal note says the bill may affect state finances, but provides no cost estimate.

  • Local-government and State Highway Fund impacts are listed as none.
  • The bill authorizes broader pharmacist services and requires some laboratory regulations. It does not estimate staffing or other state costs.
  • The Board could require liability insurance for pharmacists using the new prescribing authority; the bill does not itself require it.
  • The supplied material does not estimate costs for patients, pharmacists, insurers or health plans.

What is unclear#

  • The bill’s explanatory digest says opioids may be prescribed under this authority in line with medication-assisted-treatment protocols. But the operative text bars opioids under the new authority. Existing medication-assisted-treatment authority remains in other law; the supplied text does not resolve this conflict.
  • “Previously diagnosed,” “acute” and “adequate liability insurance” are not defined here. “Self-limiting” is defined only as a condition that generally lasts a limited time.
  • The Board may set the scope and standard of care for new prescribing and refills, but the bill does not require it to adopt those particular rules. It gives no timelines, patient follow-up rules or appeal process.
  • The supplied bill text is incomplete, ending during the health-insurance amendments. The explanatory digest says those amendments preserve existing coverage requirements, but the full later provisions could not be checked.
  • The parent statutes are not supplied. The digest describes some existing pharmacist authority, but the exact current law and all changes to it could not be independently verified against those statutes.
  • The supplied material gives no start date. Passage is uncertain.

Case for#

  • A possible argument for the bill is that pharmacists could provide certain treatment and refills without first getting approval from another practitioner.
  • Letting pharmacists order tests and perform waived tests could make some testing part of care within their authorized scope.
  • Allowing pharmacists to direct qualifying exempt laboratories without a collaborative practice agreement could remove that specific condition.
  • The bill gives the Pharmacy Board authority to set scope and standards for the new prescribing and refill services.

Case against#

  • The bill creates broad new authority but does not itself set detailed clinical rules, timelines or follow-up requirements. The Board’s authority to set some key rules is optional.
  • The conflict between the digest and bill text on opioids makes the scope of the new authority uncertain.
  • Broader testing and specimen collection authority could raise questions about training, safety and oversight that the supplied text does not answer.
  • The state may face costs, but the fiscal note gives no estimate; the bill also does not explain how any new services would be paid for.